The expression and identity of MYB-NFIB fusion transcripts were studied using reverse transcriptase polymerase chain reaction (RT-PCR) and nucleotide sequence analyses.     ///    " To investigate genetic alterations in lacrimal gland adenoid cystic carcinomas (ACCs) with emphasis on the MYB-NFIB fusion oncogene and its downstream targets, MYB rearrangements, and copy number alterations in relation to clinical data and survival. "    ///    "mRNA or protein expression of MYB-NFIB, MYB, and its down stream targets. "    ///    "As a control, we also studied the expression of MYB-NFIB in 19 non-ACC lacrimal gland tumors. "    ///    Our findings show that lacrimal gland ACCs are genetically and clinically similar to their salivary gland counterparts and that MYB-NFIB is a clinically useful diagnostic biomarker for ACC.     ///    Quantitative polymerase chain reaction (PCR) and immunohistochemistry were used to evaluate the expression of MYB/MYB-NFIB target genes.     ///    The MYB-NFIB fusion was expressed in 7 of 14 ACCs.     ///    Neither MYB-NFIB fusion nor any copy number alteration correlated with survival.     ///    "Lacrimal gland ACCs are frequently positive for the MYB-NFIB fusion, overexpress MYB and its downstream targets, and have genomic profiles characterized by losses involving 6q, 12q, and 17p, and gains involving 19q, 8q, and 11q. "